MedTrace Logo

A Study of Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents With Depressive Disorder

NCT03395353 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 151

Last updated 2021-06-18

Study results available
· View outcomes & findings →

Summary

The purpose of this long-term study is to evaluate the safety and efficacy of duloxetine hydrochloride in Japanese children and adolescents with depressive disorder.

Conditions

  • Depressive Disorder

Interventions

DRUG

Duloxetine Hydrochloride

Administered orally

Sponsors & Collaborators

Principal Investigators

  • Shionogi Clinical Trials Administrator Clinical Support Help Line · Shionogi

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
9 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-29
Primary Completion
2020-07-04
Completion
2020-07-04
FDA Drug
Yes

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03395353 on ClinicalTrials.gov